Canadian Cancer Trials Group Bulletins

General


Recent Publication

IND.207 - A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma

IND.207 was a multicenter, open label, single-arm, two-stage phase II study of PF-03446962 in patients with malignant pleural mesothelioma (MPM) and progressive disease after platinum-based chemotherapy. In total, 17 patients were enrolled, but no partial or complete responses were observed. The trial did not meet the prespecified response criterion for moving to the second stage. There were only three grade 3 (G3) or higher non-hematological toxicities observed and just one episode of G3 lymphopenia. In conclusion, PF-03446962, despite being generally well tolerated, failed to demonstrate efficacy in the treatment of advanced MPM as a single agent. There are no plans for further investigation of this agent in MPM.

Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA. A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207 (ONLINE). J Thoracic Oncol 2016.

http://www.sciencedirect.com/science/article/pii/S1556086416306062